The estimated Net Worth of Jonathan L. Guarino is at least $332 ezer dollars as of 15 December 2021. Mr Guarino owns over 1,000 units of Soligenix Inc stock worth over $37,840 and over the last 5 years he sold SNGX stock worth over $0. In addition, he makes $294,084 as Sr. VP és CFO & Corp. Sec. at Soligenix Inc.
Mr has made over 2 trades of the Soligenix Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of SNGX stock worth $700 on 15 December 2021.
The largest trade he's ever made was buying 10,000 units of Soligenix Inc stock on 14 December 2021 worth over $7,100. On average, Mr trades about 1,222 units every 0 days since 2019. As of 15 December 2021 he still owns at least 11,000 units of Soligenix Inc stock.
You can see the complete history of Mr Guarino stock trades at the bottom of the page.
Jonathan L. Guarino CPA, CGMA is the Sr. VP, CFO & Corp. Sec. at Soligenix Inc.
As the Sr. VP és CFO & Corp. Sec. of Soligenix Inc, the total compensation of Mr CGMA at Soligenix Inc is $294,084. There are 5 executives at Soligenix Inc getting paid more, with Dr. Christopher J. Schaber Ph.D. having the highest compensation of $810,303.
Mr CGMA is 48, he's been the Sr. VP és CFO & Corp. Sec. of Soligenix Inc since . There are 10 older and 1 younger executives at Soligenix Inc. The oldest executive at Soligenix Inc is Richard L. Dunning, 75, who is the Exec. Officer.
Jonathan's mailing address filed with the SEC is C/O SOLIGENIX, INC., 29 EMMONS DRIVE, SUITE B-10, PRINCETON, NJ, 08540.
Over the last 15 years, insiders at Soligenix Inc have traded over $502,220 worth of Soligenix Inc stock and bought 775,279 units worth $1,096,136 . The most active insiders traders include Randal Jintrexon Corp Kirk, Jerome B Zeldis és Spacavazza Paolo Leadiant B.... On average, Soligenix Inc executives and independent directors trade stock every 115 days with the average trade being worth of $91,349. The most recent stock trade was executed by Richard Straube on 18 May 2022, trading 8,000 units of SNGX stock currently worth $4,000.
soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Soligenix Inc executives and other stock owners filed with the SEC include: